doxorubicin,nivolumab
teva,bms,sopherion
['nivahl trial']
ready for another exciting day at #ash22 after coffee and beignets. looking forward to present an update of apd1 based 1st-line hl treatment in our nivahl trial (abstract 729). come join us at 10:30am in 265-268 for an outstanding hl session. 
Physician Scientist @UKKoeln & @MPIAGE. Hemato-Oncology, Lymphoma, Immunotherapy. Views are mine & no advise, RT/like no endorsement. COI: https://t.co/lOCrBZDrQP